Korchounov Alexei, Winter Yaroslav, Rössy Wolfgang
Parkinson Department, Marienhospital Kevelaer, Kevelaer, Germany.
Clin Neuropharmacol. 2012 May-Jun;35(3):121-4. doi: 10.1097/WNF.0b013e31823b1da8.
To investigate prokinetic and antidepressive effects of rasagiline in de novo Parkinson disease (PD).
Patients with newly diagnosed PD with comorbid untreated depression were randomly assigned to rasagiline monotherapy 1 or 2 mg/d. Unified Parkinson's Disease Rating Scale Part 2 (Activity of Daily Living) and Part 3 (Motor Function), and Hamilton Depression Rating Scale (HDRS) assessments were carried out by a blinded investigator in each patient at baseline and after 8 weeks of rasagiline treatment.
Both groups showed equal motor improvement at the end point. The improvements of HDRS score and activity of daily living were significantly more pronounced with rasagiline, 2 mg/d, than rasagiline, 1 mg/d (P = 0.0002). The treatment with rasagiline, 2 mg/d, improved symptoms in all HDRS core depression symptoms and specifically those not considered to be influenced by motor function: mood, guilt, psychic anxiety, and hypochondria.
Our results suggest that antidepressive effect seen in higher dosage of rasagiline may be not related to the motor improvement.
研究雷沙吉兰对初发帕金森病（PD）的促动力和抗抑郁作用。
将新诊断为PD且合并未经治疗的抑郁症患者随机分为雷沙吉兰单药治疗组，剂量为1或2mg/d。由一名盲法研究者在基线时以及雷沙吉兰治疗8周后，对每位患者进行统一帕金森病评定量表第2部分（日常生活活动）和第3部分（运动功能）以及汉密尔顿抑郁评定量表（HDRS）评估。
两组在终点时运动改善程度相同。与1mg/d雷沙吉兰相比，2mg/d雷沙吉兰使HDRS评分和日常生活活动的改善更为显著（P = 0.0002）。2mg/d雷沙吉兰治疗改善了所有HDRS核心抑郁症状，特别是那些被认为不受运动功能影响的症状：情绪、内疚感、精神性焦虑和疑病症状。
我们的结果表明，高剂量雷沙吉兰的抗抑郁作用可能与运动改善无关。
